🏛️ Verified NIH Record • Updated 2026-08-12
A Study of Blood Based Biomarkers for Pancreas Adenocarcinoma (NCT03334708)
🟢 Recruiting Interventional Protocol 📊 Observational Clinical Research Sponsor: Memorial Sloan Kettering Cancer Center
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to develop a minimally invasive test to diagnose pancreatic cancer at early stages of disease and monitor response to treatment.
Who can join: To join this study, participants generally need to meet the listed inclusion criteria (27 items) and avoid the listed exclusions (23 items).
Location: Memorial Sloan Kettering Monmouth (All protocol activities) — Middletown, New Jersey
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistCheck every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).
Usually NOT eligible if any of the following apply:
- Exclusion Criteria: Cohort 1: Advanced Pancreatic Cancer Cohort Exclusion Criteria
- Prior chemotherapy or radiation therapy for pancreatic cancer within the last 3 months in the localized setting
- Active second malignancy, unless low grade malignancy
- Any medical or psychiatric condition that may interfere with ability to comply with protocol procedures Cohort 2: Operable Pancreatic Cancer Cohort Exclusion Criteria
- Neoadjuvant chemotherapy or radiation therapy is planned
- Active second malignancy, unless low grade malignancy
- Any medical or psychiatric condition that may interfere with ability to comply with protocol procedures Cohort 3: Acute Benign Pancreatic Pathology Control Exclusion Criteria
- Active or prior malignancy, except prior non-melanoma skin cancer
- Proven to be a carrier of a cancer susceptibility gene or family history concerning for genetic predisposition to cancer
- Any medical or psychiatric condition that may interfere with ability to comply with protocol procedures Cohort 4: Chronic Benign Pancreatic Pathology Control Exclusion Criteria
- Active or prior malignancy, except prior non-melanoma skin cancer
- Proven to be a carrier of a cancer susceptibility gene or family history concerning for genetic predisposition to cancer
🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.
📍 All Participating Trial Locations (13 Sites)
- Memorial Sloan Kettering Monmouth (All protocol activities) — Middletown, New Jersey
- Memorial Sloan Kettering Bergen (All protocol activities) — Montvale, New Jersey
- Cold Springs Harbor Laboratory (Specimen Analysis) — Cold Spring Harbor, New York
- Memorial Sloan Kettering Cancer Center @ Commack (All Protocol Activities) — Commack, New York
- Memorial Sloan Kettering Westchester (All protocol activities) — Harrison, New York
- New York University — New York, New York
- Memorial Sloan - Kettering Cancer Center — New York, New York
- Memorial Sloan Kettering Basking Ridge (All protocol activities) — New York, New York
- Weill Cornell Medical Center — New York, New York
- Memorial Sloan Kettering Nassau (All protocol activities) — Rockville Centre, New York
- Sha'are Zedek Medical Center — Jerusalem,
- Weizmann Institute of Science — Rehovot,
- Sheba Medical Center — Tel Litwinsky,
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.